Familial Mediterranean fever: 2026 so far

Registry and surveys clarified control, spacing, and tapering variability.

In January 2026 to September 2026, several real-world reports added detail on IL-1 blockade (medicines that calm inflammation by blocking interleukin-1) after colchicine resistance, especially canakinumab and anakinra. Registry and cohort data described many patients having months without attacks and lower inflammation markers. They also showed that complete control of both symptoms and inflammation tests happened in a smaller share, and that tolerability and retention differed by drug in some pediatric data. Other reports showed that dose-reduction strategies are not uniform. Canakinumab spacing (longer time between injections) worked for some children but not others, and anakinra tapering/stopping plans varied widely across clinicians. This helps set expectations about what has been seen in routine care -- including practical dosing changes and some reported serious events, whose relationship to treatment could not be established in the pediatric comparison -- without showing which IL-1 blocker or tapering plan is best for any one person.

Research covered in: January 2026, February 2026, March 2026, April 2026, July 2026, August 2026

Evidence expanded from stopping outcomes to formulation switching and adherence links.

So far in 2026, several studies looked at what happens when colchicine is stopped or modified, and who stays well afterward. Adult and pediatric discontinuation reports described that some people -- often in selected milder situations -- remained attack-free. However, inflammation markers could still rise, and sustained colchicine-free remission was uncommon in a large pediatric follow-up cohort. Treatment-adjustment evidence also included a pediatric real-world report where switching colchicine formulation (coated to compressed) was followed by fewer attacks overall. Improvement was not uniform, and some still needed escalation to IL-1 inhibitors. Overall, these reports suggest that symptoms and inflammation tests may not improve (or worsen) in the same way after colchicine changes, and that results after stopping or switching differ across people and study groups.

Research covered in: January 2026, June 2026, September 2026

Studies highlighted adherence measurement gaps and uneven access to biologics.

In reports from January 2026 to September 2026, day-to-day management repeatedly showed up as something that can shape how FMF affects life. Pediatric studies found that measured colchicine adherence (how regularly doses are taken) was often worse than families reported, and it was linked with more school absenteeism. Adult studies linked regular colchicine use with fewer attacks. Small intervention work suggested interactive or game-based training improved self-efficacy (confidence in managing the condition), quality of life, and reported compliance in children. Other studies linked illness perceptions and social factors (like income and age) to adherence differences. Separately, a multi-country survey described wide variation in availability and reimbursement restrictions for IL-1 blockers, showing that access can limit treatment options even when medicines exist. Together, these findings point to routines, education/support, and health-system access as factors that can influence outcomes alongside medication choice.

Research covered in: January 2026, February 2026, April 2026, June 2026, September 2026

Matched-cohort and biomarker studies kept pointing to persistent inflammation signals.

In January 2026 to September 2026, studies discussing amyloidosis (a protein buildup that can damage organs) often connected risk with ongoing inflammation and higher disease activity, including signals present between attacks. One nationwide matched cohort study reported amyloidosis was much more frequent in FMF than in matched controls. Other observational studies linked amyloidosis to patterns such as higher ongoing inflammation, more frequent/longer attacks, and kidney involvement once amyloidosis develops. Several groups tested monitoring approaches (e.g., blood-count composite indices and comparisons of CRP versus SAA), generally describing them as research tools that still need validation rather than established standards. In practical terms, the months covered continued to highlight persistent inflammation -- even when symptoms are quieter -- as part of how amyloidosis risk is discussed, while the best routine way to measure that risk is still not settled.

Research covered in: March 2026, April 2026, June 2026, July 2026, August 2026, September 2026

Broader sequencing and cohort data reinforced limits of genetics alone.

So far in 2026, multiple reports reinforced that MEFV testing (a gene test linked to FMF) can support diagnosis but often does not give a simple yes/no answer. This was especially true when only one variant is found, or when variants appear in people tested for other reasons. Stepwise approaches (including broader sequencing after limited panels) sometimes found additional variants, including in other autoinflammatory genes (genes linked to inflammation conditions). Large pediatric data also showed diagnosis commonly took many months, with family history shortening the path. Several studies focused on telling FMF apart from look-alike conditions using symptom patterns and basic inflammation tests, with additional tools (e.g., stool calprotectin in GI symptoms) helping in specific contexts. This means diagnostic certainty often comes from combining symptom history, inflammation testing, and genetics over time, rather than relying on a single test result.

Research covered in: April 2026, June 2026, July 2026, September 2026